Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: Synergy or redundancy?

Endocrinology

Volumn 148, Issue 2, 2007, Pages 886-895

  Coughlan, Melinda T ^a   Thallas Bonke, Vicki ^a   Pete, Josefa ^a   Long, David M ^a   Gasser, Anna ^a   Tong, David C K ^a   Arnstein, Maryann ^a   Thorpe, Suzanne R ^b   Cooper, Mark E ^a,c   Forbes, Josephine M ^a,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; PROTEIN KINASE C; RAMIPRIL; RAS PROTEIN; STREPTOZOCIN; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG INHIBITION; DRUG POTENTIATION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; MITOCHONDRIAL MEMBRANE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINARY EXCRETION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CYTOSOL; DIABETES MELLITUS, EXPERIMENTAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME ACTIVATION; GLYCOSYLATION END PRODUCTS, ADVANCED; KIDNEY; LYSINE; MALE; MITOCHONDRIA; NF-KAPPA B; OXIDATIVE STRESS; PROTEIN KINASE C; RAMIPRIL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; RENIN-ANGIOTENSIN SYSTEM; SUPEROXIDE DISMUTASE; THIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846448808     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-1300     Document Type: Article

References (51)

1. Brownlee M 2001 Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820
2. Cooper ME 2001 Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 44:1957-1972
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD 1993 The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462
4. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869
5. Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, Raffaele J, Tsalamandris C 2001 Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 37:890-899
6. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M 2000 Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790
7. Scivittaro V, Ganz MB, Weiss MF 2000 AGEs induce oxidative stress and activate protein kinase C-β(II) in neonatal mesangial cells. Am J Physiol Renal Physiol 278:F676-F683
8. Baynes JW 1991 Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412
9. Osicka TM, Yu YX, Panagiotopoulos S, Clavant SP, Kiriazis Z, Pike RN, Pratt LM, Russo LM, Kemp BE, Comper WD, Jerums G 2000 Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 49:87-93
10. Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J 2000 Angiotensin II activates nuclear transcription factor κB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res 86:1266-1272
11. Lee FT, Cao Z, Long DM, Panagiotopoulos S, Jerums G, Cooper ME, Forbes JM 2004 Interactions between angiotensin II and NFκB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol 15:2139-2151
12. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A 1986 Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632
13. Soulis T, Thallas V, Youssef S, Gilbert RE, McWilliam B, Murray-McIntosh RP, Cooper ME 1997 Advanced glycation end products and the receptor for advanced glycated end products co-localise in organs susceptible to diabetic microvascular injury: immunohistochemical studies. Diabetologia 40:619-628
14. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM 2003 RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162:1123-1137
15. Morcos M, Sayed AA, Bierhaus A, Yard B, Waldherr R, Merz W, Kloeting I, Schleicher E, Mentz S, Abd el Baki RF, Tritschler H, Kasper M, Schwenger V, Hamann A, Dugi KA, Schmidt AM, Stern D, Ziegler R, Haering HU, Andrassy M, van der Woude F, Nawroth PP 2002 Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 51:3532-3544
16. De Vriese AS, Tilton RG, Stephan CC, Lameire NH 2001 Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 12:1734-1741
17. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R 2002 Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51:3090-3094
18. Schrijvers BF, Flyvbjerg A, Tilton RG, Lameire NH, De Vriese AS 2006 A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant 21:324-329
19. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP 2005 Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:876-886
20. Thomas MC, Tikellis C, Burns WM, Bialkowski K, Cao Z, Coughlan MT, Jandeleit-Dahm K, Cooper ME, Forbes JM 2005 Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 16:2976-2984
21. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K 2002 Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 13:2478-2487
22. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, Osicka TM 2002 Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51:3274-3282
23. Bunag RD 1973 Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol 34:279-282
24. O'Brien RC, Allen TJ, Cooper ME, Bach L, Jerums G 1988 Glomerular filtration rate in early experimental diabetes. J Diabetes Complications 2:8-11
25. Cefalu WT, Wang ZQ, Bell-Farrow A, Kiger FD, Izlar C 1994 Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. Clin Chem 40:1317-1321
26. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, Wagle D, Jerums G, Cooper ME 2001 Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44:108-114
27. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW 2002 Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61:939-950
28. Mohanty JG, Jaffe JS, Schulman ES, Raible DG 1997 A highly sensitive fluorescent micro-assay of H2O2 release from activated human leukocytes using a dihydroxyphenoxazine derivative. J Immunol Methods 202:133-141
29. Baines CP, Zhang J, Wang GW, Zheng YT, Xiu JX, Cardwell EM, Bolli R, Ping P 2002 Mitochondrial PKCε and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCε-MAPK interactions and differential MAPK activation in PKCε-induced cardioprotection. Circ Res 90:390-397
30. Forbes JM, Bonnet F, Russo LM, Burns WC, Cao Z, Candido R, Kawachi H, Allen TJ, Cooper ME, Jerums G, Osicka TM 2002 Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria. J Hypertens 20:985-992
31. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME 2003 The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 17:1762-1764
32. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper ME, Allen TJ 2004 Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53:1813-1823
33. Peppa M, Brem H, Cai W, Zhang JG, Basgen J, Li Z, Vlassara H, Uribarri J 2006 Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). Am J Nephrol 26:430-436
34. Alderson NL, Chachich ME, Youssef NN, Beattie RJ, Nachtigal M, Thorpe SR, Baynes JW 2003 The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 63:2123-2133
35. Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J, Brownlee M 1998 Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 101:1142-1147
36. Thornalley PJ, Langborg A, Minhas HS 1999 Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344(Pt 1):109-116
37. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW 2000 Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 275:21177-21184
38. Yan SD, Schmidt AM, Anderson GM, Zhang JH, Brett J, Zou YS, Pinsky D, Stern D 1994 Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors binding proteins. J Biol Chem 269:9889-9897
39. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL 2001 Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685-E694
40. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Haring HU, Schleicher E, Nawroth PP 2001 Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes 50:2792-2808
41. Liu H, Zhu L, Zheng F, Vlassara H 2005 Overexpression of AGE-receptor-1 (AGE-R1) in mice prevent AGE accumulation and delays diabetic renal injury. Diabetes 54:A21-B
42. Lu C, He JC, Cai W, Liu H, Zhu L, Vlassara H 2004 Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci USA 101:11767-11772
43. Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER, Bassal S, El-Osta A, Long DM, Panagiotopoulos S, Jerums G, Osicka TM, Cooper ME 2005 Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 16:2363-2372
44. Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, Haller H, Cooper ME, Forbes JM 2004 Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-α-dependent pathway. Diabetes 53:2921-2930
45. Nagahama T, Hayashi K, Ozawa Y, Takenaka T, Saruta T 2000 Role of protein kinase C in angiotensin II-induced constriction of renal microvessels. Kidney Int 57:215-223
46. Christlieb AR 1976 Renin-angiotensin-aldosterone system in diabetes mellitus. Diabetes 25:820-825
47. Bonnet F, Candido R, Carey RM, Casley D, Russo LM, Osicka TM, Cooper ME, Cao Z 2002 Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade. J Hypertens 20:1615-1624
48. Wilkes BM 1987 Reduced glomerular angiotensin II receptor density in diabetes mellitus in the rat: time course and mechanism. Endocrinology 120:1291-1298
49. Ballermann BJ, Skorecki KL, Brenner BM 1984 Reduced glomerular angiotensin II receptor density in early untreated diabetes mellitus in the rat. Am J Physiol 247:F110-F116
50. Kennefick TM, Oyama TT, Thompson MM, Vora JP, Anderson S 1996 Enhanced renal sensitivity to angiotensin actions in diabetes mellitus in the rat. Am J Physiol 271:F595-F602
51. Hollenberg NK, Price DA, Fisher ND, Lansang MC, Perkins B, Gordon MS, Williams GH, Laffel LM 2003 Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 63:172-178